UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 10.

Mangani, D; Weller, M; Seyed Sadr, E; Willscher, E; Seystahl, K; Reifenberger, G; Tabatabai, G; Binder, H; Schneider, H (2016). Limited role for transforming growth factor-β pathway activation-mediated escape from VEGF inhibition in murine glioma models. Neuro-Oncology, 18(12):1610-1621.

Szabo, E; Schneider, H; Seystahl, K; Rushing, E J; Herting, F; Weidner, K M; Weller, M (2016). Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo. Neuro-Oncology, 18(9):1242-1252.

Furtner, J; Schöpf, V; Seystahl, K; Le Rhun, E; Rudà, R; Roelcke, U; Koeppen, S; Berghoff, A S; Marosi, C; Clement, P; Faedi, M; Watts, C; Wick, W; Soffietti, R; Weller, M; Preusser, M (2016). Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. Neuro-Oncology, 18(3):401-407.

Seystahl, K; Tritschler, I; Szabo, E; Tabatabai, G; Weller, M (2015). Differential regulation of TGF-β-induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma. Neuro-Oncology, 17(2):254-265.

Seystahl, K; Weller, M (2015). Molekulare Marker werden zunehmend wichtiger Therapieoptionen bei höhergradigen Gliomen. InFo Onkologie und Haematologie:24-27.

Seystahl, K; Könnecke, H; Sürücü, O; Baumann, C R; Poryazova, R (2014). Development of a short sleeper phenotype after third ventriculostomy in a patient with ependymal cysts. Journal of Clinical Sleep Medicine, 10(2):211-213.

Seystahl, K; Weller, M; Bozinov, O; Reimann, R; Rushing, E (2014). Neuropathological characteristics of progression after prolonged response to bevacizumab in multifocal hemangioblastoma. Oncology Research and Treatment, 37(4):209-212.

Seystahl, K; Wiestler, B; Hundsberger, T; Happold, C; Wick, W; Weller, M; Wick, A (2013). Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II and Grade III Gliomas. European Neurology, 69(2):95-101.

Riklin, C; Seystahl, K; Hofer, S; Happold, C; Winterhalder, R; Weller, M (2012). Antiangiogenic treatment for multiple CNS hemangioblastomas. Onkologie, 35(7-8):443-445.

Seystahl, K; Weller, M (2012). Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? Expert Opinion on Investigational Drugs, 21(5):605-617.

This list was generated on Fri Jul 28 06:03:23 2017 CEST.